Acelrx Pharmaceuticals (ACRX) 9.64 $ACRX
AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:05PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three months ended March 31, 2014.
AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014
PR Newswire - Fri May 02, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2014 financial results after market close on Thursday, May 8, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 8, 2014 to discuss the financial results and provide a corporate update.
AcelRx Pharmaceuticals Announces Zalviso(TM) and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting
PR Newswire - Thu May 01, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and ARX-04 data presentations will be made at the American Pain Society's (APS) 33rd Annual Scientific Meeting held on April 30 to May 3 in Tampa, Florida. The APS Annual Scientific Meeting is the premier pain meeting in the United States with more than 1,000 scientists and clinicians specializing in pain and pain management expected to attend.
Equities to Watch in the Health Care Sector -- Research on Novadaq Technologies, Quest Diagnostics, Cooper Cos, and AcelRx Pharma
PR Newswire - Tue Apr 15, 11:56AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Novadaq Technologies Inc. (NASDAQ: NVDQ), Quest Diagnostics Inc. (NYSE: DGX), The Cooper Cos Inc. (NYSE: COO) and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free technical research on NVDQ, DGX, COO and ACRX can be downloaded upon signing up at:
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Apr 04, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows:
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
PR Newswire - Tue Mar 25, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO). Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most recently operating in this capacity at VIVUS, Inc., a commercial-stage biopharmaceutical company. Mr. Morris will be responsible for managing the company's finance operations, its information systems and human resource and investor relations functions. Jim Welch, who had served as CFO since October 2010, departed the company to pursue other business opportunities.
AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
PR Newswire - Fri Mar 07, 3:45PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference:
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why AcelRx Pharmaceuticals, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 12:42PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of specialty drug company AcelRx...
GMO Inside Announces Campaign to Get GMOs Out of Starbucks' Dairy
PR Newswire - Tue Mar 04, 9:00AM CST
Green America's GMO Inside campaign today launched a major push to get Starbucks, America's largest coffee chain with more than 20,000 stores in 62 countries, to serve only organic milk sourced from cows not fed GMOs. In early January, GMO Inside made worldwide headlines when its social media campaign led General Mills to announce that it would drop genetically modified ingredients in basic Cheerios.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:05PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.
AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
PR Newswire - Mon Feb 24, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results and provide a corporate update.
PAREXEL Simplifies Drug Development Journey From Science To New Treatments
PR Newswire - Wed Feb 12, 5:00AM CST
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
PR Newswire - Wed Feb 05, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows:
Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:47AM CST
Cempra's shares fell nearly 11% yesterday, continuing the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:19AM CST
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout?
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:05PM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three months ended March 31, 2014.
AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014
PR Newswire - Fri May 02, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2014 financial results after market close on Thursday, May 8, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 8, 2014 to discuss the financial results and provide a corporate update.
AcelRx Pharmaceuticals Announces Zalviso(TM) and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting
PR Newswire - Thu May 01, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and ARX-04 data presentations will be made at the American Pain Society's (APS) 33rd Annual Scientific Meeting held on April 30 to May 3 in Tampa, Florida. The APS Annual Scientific Meeting is the premier pain meeting in the United States with more than 1,000 scientists and clinicians specializing in pain and pain management expected to attend.
Equities to Watch in the Health Care Sector -- Research on Novadaq Technologies, Quest Diagnostics, Cooper Cos, and AcelRx Pharma
PR Newswire - Tue Apr 15, 11:56AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Novadaq Technologies Inc. (NASDAQ: NVDQ), Quest Diagnostics Inc. (NYSE: DGX), The Cooper Cos Inc. (NYSE: COO) and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free technical research on NVDQ, DGX, COO and ACRX can be downloaded upon signing up at:
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Apr 04, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows:
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
PR Newswire - Tue Mar 25, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO). Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most recently operating in this capacity at VIVUS, Inc., a commercial-stage biopharmaceutical company. Mr. Morris will be responsible for managing the company's finance operations, its information systems and human resource and investor relations functions. Jim Welch, who had served as CFO since October 2010, departed the company to pursue other business opportunities.
AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
PR Newswire - Fri Mar 07, 3:45PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference:
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why AcelRx Pharmaceuticals, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 12:42PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of specialty drug company AcelRx...
GMO Inside Announces Campaign to Get GMOs Out of Starbucks' Dairy
PR Newswire - Tue Mar 04, 9:00AM CST
Green America's GMO Inside campaign today launched a major push to get Starbucks, America's largest coffee chain with more than 20,000 stores in 62 countries, to serve only organic milk sourced from cows not fed GMOs. In early January, GMO Inside made worldwide headlines when its social media campaign led General Mills to announce that it would drop genetically modified ingredients in basic Cheerios.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:05PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.
AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
PR Newswire - Mon Feb 24, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results and provide a corporate update.
PAREXEL Simplifies Drug Development Journey From Science To New Treatments
PR Newswire - Wed Feb 12, 5:00AM CST
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
PR Newswire - Wed Feb 05, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows:
Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:47AM CST
Cempra's shares fell nearly 11% yesterday, continuing the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:19AM CST
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout?
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
